3 Results for "

RGD-binding integrins

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "RGD-binding integrins" in MCE Product Catalog:

2
2 Cited Publications
Cat. No.: HY-134130
CAS No.: 2023788-32-9
Purity:  99.80%
Target:  

Integrin

Research Areas:  

Inflammation/Immunology

Integrin modulator 1 is a potent and selective α4β1 integrin agonist, with an IC50 of 9.8 nM for RGD-binding α4β1. Integrin modulator 1 increases cell adhesion mediated by α4β1 integrin, with an EC50 of 12.9 nM .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99291
CAS No.: 892553-42-3
Synonyms: LM609; MEDI-522

Target:  

Integrin Apoptosis Akt

Research Areas:  

Cancer

Etaracizumab (LM 609) is an αvβ3 integrin IgG mAb. Etaracizumab is developed to target αvβ3+ cancer cells via NK cell-mediated cytotoxicity. Etaracizumab sterically hinders access of large ligands to the RGD-binding pocket, without obstructing it. Etaracizumab decreases p-Akt in vitro. Etaracizumab can decrease cancer proliferation and invasion. Etaracizumab induces tumor cell apoptosis, and inhibition ofαvβ3-mediated cell adhesion, endothelial cell migration and osteoclast-mediated bone resorption. Etaracizumab can be studied in anti-tumor research against cancers such as ovarian cancer, metastatic melanoma as well as advanced solid tumors. Recommend Isotype Control: Human IgG1 kappa, Isotype Control (HY-P99001) .
loading...
    loading...
Cat. No.: HY-P1654
CAS No.: 932699-03-1
Target:  

Integrin

Research Areas:  

Cancer

A20FMDV2 is a highly selective αvβ6 integrin inhibitor with human IC50 values of 3 nM and binds with at least 1000-fold selectivity over other RGD-binding integrins. A20FMDV2 binds to the integrin’s RGD-binding site, induces rapid integrin internalization, and delays post-internalization integrin recycling to the cell surface. A20FMDV2 can be used for the research of pancreatic cancer, breast cancer, colorectal cancer, ovarian cancer, oral squamous cell carcinoma .
loading...
    loading...